Options
Title
Verfahren und Mittel zur Modifikation humaner Angiogenese
Date Issued
2002
Author(s)
Patent No
2001-10109466
Abstract
Die vorliegende Erfindung betrifft ein Verfahren und Mittel zur Modifikation humaner Angiogenese, wobei die in diesen Verfahren eingesetzten Mittel Nucleinsaeuren, Nucleinsaeurekomplexe oder Antikoerper dagegen sein koennen.
WO 200268636 A UPAB: 20021125 NOVELTY - Nucleic acid (I), suitable as a functional component of a biologically active metallo-ribonucleoprotein complex, is new. DETAILED DESCRIPTION - Nucleic acid (I), suitable as a functional component of a biologically active metallo-ribonucleoprotein complex: (i) is a sequence obtained by reverse transcription of total placental RNA with the RNA component of porcine angiotropin (ARNA) I-specific primers (sequences fully defined i the specification), or its fragments; (ii) comprises any of 13 specified sequences (with 13-235 nucleotides (nt) fully defined in the specification, all RNAs); (iii) is derived from (i) or (ii) by substitution, addition, inversion and/or deletion of one or more nt; (iv) hybridizes to (i)-(iii) or their fragments; or (v) is the complement of (i)-(ii) or their fragments. INDEPENDENT CLAIMS are also included for the following: (1) a vector that contains (I) and optionally regulatory elements; (2) a host cell containing the vector of (a); (3) a nucleic acid complex (A) comprising (I) and metal ions and/or proteins; (4) an antibody (Ab) that recognizes, and binds to, (A) specifically; (5) transporting a nucleic acid (NA) into eukaryotic cells, cell cultures or tissue; (6) inducing or inhibiting angiogenesis in mammals; (7) a diagnostic or pharmaceutical composition containing any of (I) or the materials of (a)-(d); and (8) reducing proliferation and/or inducing differentiation of cells by introducing (I) or the materials of (a)-(d). ACTIVITY - Vulnerary; cytostatic; antipsoriatic; antidiabetic; ophthalmological; cardiant. No biological data is given. MECHANISM OF ACTION - (I) reduce activity and/or expression of the L27a gene (encoding a ribosomal protein) and may act by ribozyme, antisense or co-suppression mechanisms. USE - (I), and also related complexes, vectors, host cells and antibodies are useful: (i) to induce angiogenesis ((I) is in sense orientation, e.g. for promoting wound healing and to induce neovascularization of diseased cardiac tissue) or to inhibit angiogenesis ((I) is in antisense orientation, e.g. for treating tumors and diabetic retinopathy); (ii) to transfer genetic information into cells; (iii) for selective alteration in the nucleic acid content of cells; (iv) for reducing proliferation and/or inducing differentiation of cells, e.g. stem, degenerative or tumor cells, also diseased, e.g. psoriatic cells; (v) for (I), to isolate and/or transport binding proteins; (vi) for diagnosis, e.g. of changes in growth of blood vessels; and in vitro, for causing targeted changes in the morphology of cells and for studying association of nucleic acids or their complexes. ADVANTAGE - Modification of NA with (I) makes NA transportable into target cells by ARPM, calgranulin C or similar proteins.
Language
de
Patenprio
DE 2001-10109466 A: 20010228